Cancer drug cabozantinib takes on rare, Fast-Growing tumors
NCT ID NCT04412629
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests the drug cabozantinib in 35 people with high-grade neuroendocrine tumors that have worsened after at least one prior treatment. These are rare, fast-growing cancers with limited options. The study aims to see if cabozantinib can shrink tumors or slow their growth. Participants take the drug daily on an empty stomach, and researchers track response, survival, and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cabozantinib (a targeted cancer drug, also called Cabometyx)
- What this could lead to
- If it works, this could offer a new treatment option for people with aggressive neuroendocrine tumors that have stopped responding to standard chemotherapy.
- What could go wrong
- This is a small, early-phase trial (35 people) with no control group, so results may not be definitive. Cabozantinib can cause side effects like fatigue, diarrhea, and high blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE NEUROENDOCRINE NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.